Improving the effectiveness of medical rehabilitation of patients with ischemic heart disease using dihydroquercetin

Cardiovascular diseases (CVD) are a leading cause of death in all industrialized countries. Coronary heart disease (CHD) occupies a leading position among CVDs. The relevance of CHD is determined by its role in disability and mortality in the population, as well as the financial costs associated with the treatment and rehabilitation of patients. The goals of treating patients with CHD are to improve quality of life by reducing the frequency of angina attacks and preventing acute myocardial infarction. In addition to lipid metabolism disorders, hemostatic disorders play a significant role in the development and progression of CHD. In particular, increased platelet activity leads to changes in blood rheology and an increased tendency to thrombosis, which leads to impaired microcirculation. Therefore, the inclusion of agents that target pathogenic mechanisms in rehabilitation programs for such patients appears promising. One such agent is the bioflavonoid dihydroquercetin (DHA), obtained from Siberian larch wood. It stimulates tissue blood flow, stabilizes microvascular barrier function, reduces capillary wall permeability, improves blood rheology, and thereby helps reduce microvascular congestion. The aim of this study was to evaluate the effectiveness of the dietary supplement «Dihydroquercetin» (Evalar, JSC) in the comprehensive treatment of patients with coronary heart disease. The study demonstrated the positive effects of dihydroquercetin on cardiovascular disease (CVD): significant improvement in peripheral microcirculation hemodynamic parameters, a tendency toward normalization of cerebral hemodynamics, and a positive effect on lipid metabolism. This opens up new possibilities for the use of plant-based antioxidants in practical medicine.